Skip to main content
The BMJ logoLink to The BMJ
letter
. 2005 May 14;330(7500):1150.

Do selective serotonin reuptake inhibitors cause suicide?

Authors' reply to Jones, Sakinofsky and Streiner, and Mitchell

Dean Fergusson 1,2,3,4, Steve Doucette 1,2,3,4, Paul Hebert 1,2,3,4, David Healy 1,2,3,4, Stan Shapiro 1,2,3,4
PMCID: PMC557909

Editor—The low rates of attempted suicide may be the result of several factors. Most studies did not enrol patients at immediate risk of suicide, and 59% of studies (414/702) were conducted in clinical indications other than major depression. The greatest contributing factors may be the under-reporting and non-reporting of events. Of the 702 trials, 345 did not provide documentation on suicide attempts.

Given the seriousness of attempted suicide, the expectation that patients in trials be well monitored, and a well documented possible association between treatment with selective serotonin reuptake inhibitors (SSRIs) and suicidality, it is disturbing that fatal and non-fatal suicide attempts were not apparently better reported. We have no empirical evidence that under-reporting may be differential because of side effects, prompting closer external monitoring of patients taking SSRIs. Good clinical trial management dictates that blinded investigators monitor all patients for all serious adverse events.

We agree that most trials evaluated were not intended to assess suicidality and strongly advocated that large clinical trials with clinically meaningful outcomes are needed to help clinicians and regulators. Given that SSRIs reduce depression and depression is associated with suicidality, we are surprised that trials assessing the effectiveness of SSRIs in reducing suicidality have not been conducted. An appropriately designed, randomised controlled trial along with validated measures of assessing suicidality would not require many patients to examine, safely, any risk and might enable antidepressants to be used more effectively and safely. Such a trial and rating scale were designed by Eli Lilly with the Food and Drug Administration in 1991 (details forwarded on request).

Ignoring individual trials and calculating summary statistics from lumped data, as Mitchell has done, is an incorrect approach to meta-analysis. Nowhere in our Methods section do we state that we calculated odds ratios from the aggregated data. Instead, we conducted meta-analyses of randomised controlled trials using Peto's method for calculating odds ratios of rare event data. Failing to preserve the randomisation of subjects at the trial level introduces bias and confounding.1 Furthermore, simply calculating odds ratios from aggregated data fails to account for the influence of chance in small trials. By weighting each study by its precision, smaller trials have less influence than larger trials.

Given the enormous number of SSRIs prescribed, we maintain that a number needed to harm as large as 684 represents a public health concern. For every 1 million prescriptions, this translates into more than 1450 excess suicide attempts compared with those receiving placebo.

Competing interests: DH has had consultancies with, been a principal investigator or clinical trialist for, been a chairman or speaker at international symposiums for, or been in receipt of support to attend foreign meetings from: Astra, Astra-Zeneca, Boots/Knoll, Eli Lilly, Janssen-Cilag, Lorex-Synthelabo, Lundbeck, Organon, Pharmacia and Upjohn, PierreFabre, Pfizer, Rhone-Poulenc Rorer, Roche, SmithKline Beecham, Solvay, and Zeneca. DH has also been an expert witness for the plaintiff in eight legal actions involving SSRIs and has been consulted on several cases of attempted suicide, suicide, and suicide-homicide after antidepressant medication, in most of which he has offered the view that the treatment was not involved. He has also been an expert witness for the defendants (the British NHS) in a large series of lysergic acid diethylamide (LSD) and electroconvulsive therapy (ECT) cases.

References

  • 1.Egger M, Davey Smith G, Altman D. Systematic reviews in health care. Meta-analysis in context. London: BMJ Publishing, 2001.

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES